# US 10,869,919 B2 · Porcine circovirus type 3 strain, vaccine composition, method of making the same and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,919 B2
- Document ID: US10869919B2
- Status: Granted
- Kind: B2
- Application number: 16/483,941
- Filed: 2017-11-30
- Published: 2019-12-26
- Granted: 2020-12-22
- Earliest claimed: 2017-03-29
- Assignees: Pulike Biological Engineering, Inc.
- Applicants: Pulike Biological Engineering, Inc.
- Inventors: Kegong Tian; Xiangdong Li; Yan Xiao; Jinzhong Sun; Xuke Zhang
- Web page: https://patentgrep.com/patent/US10869919B2

## CPC

- A61K 39/12: Viral antigens
- A61P 31/20: for DNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2750/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A porcine circovirus type 3 virus strain and a vaccine composition prepared from the immunogenic substance of the strain are described. The porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.

## Claims

### Claim 1

A vaccine composition, wherein the vaccine composition comprises an immunogenic amount of inactivated antigen of the porcine circovirus type 3 SG strain or a culture thereof, and an adjuvant, and wherein the porcine circovirus type 3 SG strain has the accession number CCTCC NO. V201712 deposited at the China Center for Type Culture Collection.

### Claim 2 (depends on 1)

The vaccine composition according to claim 1, wherein the inactivated antigen of the porcine circovirus type 3 SG strain or the culture thereof is an inactivated whole-virus antigen of the porcine circovirus type 3 virus SG strain or the culture thereof.

### Claim 3 (depends on 2)

The vaccine composition according to claim 2, wherein the inactivated whole-virus antigen content of the porcine circovirus type 3 SG strain or the culture thereof is equal to or more than 105.0 TCID50/ml before inactivation.

### Claim 4 (depends on 2)

The vaccine composition according to claim 2, wherein the inactivated whole-virus antigen content of the porcine circovirus type 3 SG strain or the culture thereof is within a range of 105.0 to 107.0 TCID50/ml before inactivation.

### Claim 5 (depends on 2)

The vaccine composition according to claim 2, wherein the inactivated whole-virus antigen content of the porcine circovirus type 3 SG strain or the culture thereof is 106.0 TCID50/ml before inactivation.

### Claim 6 (depends on 1)

The vaccine composition according to claim 1, wherein the culture of the porcine circovirus type 3 SG strain is a culture which has been subcultured for more than one passage.

### Claim 7 (depends on 6)

The vaccine composition according to claim 6, wherein the culture of the porcine circovirus type 3 SG strain is a culture which has been subcultured for more than five passages.

### Claim 8 (depends on 7)

The vaccine composition according to claim 7, wherein the culture of the porcine circovirus type 3 SG strain is a culture which has been subcultured for 5 to 55 passages.

### Claim 9 (depends on 1)

The vaccine composition according to claim 1, wherein the adjuvant comprises white oil, and other animal oils, vegetable oils or mineral oil; or aluminum hydroxide, aluminum phosphate, and other metal salts; or a polymer-based adjuvant which contains gel particles of sodium polyacrylate in water, carbomer, squalane or squalene, ISA206 adjuvant, saponin, oil emulsion, oil in water emulsions, water-in-oil emulsion.

### Claim 10 (depends on 9)

The vaccine composition according to claim 9, wherein the adjuvant is used in an amount of 5 to 20% by volume.

### Claim 11 (depends on 10)

The vaccine composition according to claim 10, wherein the adjuvant is used in an amount of 10% by volume.

### Claim 12 (depends on 1)

A method for prevention and/or treatment of porcine circovirus type 3 related diseases by administration of an effective amount of the vaccine composition of claim 1 to a subject.